MedTrace Logo

Peptide Vaccination in Combination With Azacitidine for Patients With MDS and AML

NCT02750995 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2020-11-25

No results posted yet for this study

Summary

The purpose of this phase I study is to investigate the combination of hypomethylating agents with experimental peptide vaccination against four selected tumor antigens, known to be upregulated in response to hypomethylating agents, in patients with high risk myelodysplastic syndrome and acute myeloid leukemia.

Conditions

Interventions

BIOLOGICAL

NPMW-peptide vaccine

Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.

DRUG

Azacitidine

Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.

Sponsors & Collaborators

  • Technical University of Denmark

    collaborator OTHER

  • Daniel El Fassi

    lead OTHER

Principal Investigators

  • Daniel El Fassi, MD PhD · Herlev Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-01-02
Completion
2019-06-01

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02750995 on ClinicalTrials.gov